Medicare Part B Coinsurance Reduced: Inflation Reduction Act Impact

Under the Inflation Reduction Act, Medicare beneficiaries may experience reduced coinsurance for certain Part B drugs if drug prices surge faster than inflation rates.

Lowered Coinsurance Rates for Part B Drugs

The U.S. Department of Health and Human Services (HHS), via the Centers for Medicare & Medicaid Services (CMS), disclosed that 41 drugs available through Medicare Part B will undergo a coinsurance rate reduction from April 1 to June 30, 2024, should drug companies hike prices faster than inflation. Approximately 763,700 Medicare beneficiaries annually utilize one or more of these drugs.

Savings for Medicare Beneficiaries

As per the President’s lower-cost prescription drug law, known as the Inflation Reduction Act, eligible Medicare beneficiaries could save between $1 and $3,575 per average dose for these drugs during the mentioned timeframe, depending on individual coverage.

Government's Response

HHS Secretary Xavier Becerra praised the initiative, stating, “Thanks to President Biden’s lower cost prescription drug law, the cost of prescription drugs is coming down for people with Medicare. We are putting money back in the pockets of older Americans and people with disabilities instead of Big Pharma.” CMS Administrator Chiquita Brooks-LaSure echoed this sentiment, emphasizing the administration's commitment to curbing drug prices and ensuring affordability for all.

Rebates and Future Plans

The Inflation Reduction Act mandates drug companies to pay rebates to Medicare if prices surge faster than inflation for specific drugs. CMS plans to start invoicing prescription drug companies for owed rebates no later than fall 2025. Rebate amounts will be deposited into the Federal Supplementary Medical Insurance Trust Fund to bolster Medicare’s long-term sustainability.

Comprehensive Approach

Besides the Medicare Prescription Drug Inflation Rebate Program, the Inflation Reduction Act encompasses various provisions aimed at reducing prescription drug and healthcare costs. These include expanding eligibility for full benefits under the Low-Income Subsidy program (LIS) under Medicare Part D and capping annual out-of-pocket drug costs for Medicare Part D enrollees.

Resources and Further Information

For more details on the Medicare Prescription Drug Inflation Rebate Program and the list of Part B drugs with reduced coinsurance, refer to the official resources. Additionally, LowerDrugCosts.gov offers comprehensive information on how the Inflation Reduction Act is aiding in cost reduction for Medicare beneficiaries.